febuxostat

Febuxostat (TEI 6720) is a xanthine oxidase inhibitor.

O-Desisobutyl-O-n-propyl Febuxostat, an xanthine oxidase inhibitor.

Febuxostat (TEI 6720) sodium has the potential in gout and hyperuricemia research which is a potent, selective and non-purine inhibitor of xanthine oxidase (XO) with a Ki value of 0.6 nM [1] [2] [3].

Febuxostat 67M-1 is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and reduces the risk of gout or kidney stone formation.

Febuxostat hemihydrate is a xanthine oxidase inhibitor used to treat hyperuricemia and chronic gout.

Febuxostat 67M-4 is a derivative compound of Febuxostat 67M-1 which is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and reduces the risk of gout or kidney stone formation.

Febuxostat isopropyl isomer is an impurity of Febuxostat, a selective xanthine oxidase inhibitor with a K i of 0.6 nM [1].

Febuxostat n-butyl isomer is an impurity of Febuxostat, a selective xanthine oxidase inhibitor with a K i of 0.6 nM [1].

Febuxostat sec-butoxy acid is an impurity of Febuxostat, a selective xanthine oxidase inhibitor with a K i of 0.6 nM [1].

Febuxostat impurity 7 is a derivative of Febuxostat, a selective xanthine oxidase inhibitor with a K i of 0.6 nM [1].

Febuxostat impurity 8 is an impurity of Febuxostat, a selective xanthine oxidase inhibitor with a K i of 0.6 nM [1].

Febuxostat impurity 6 is an impurity of Febuxostat, a selective xanthine oxidase inhibitor with a K_i of 0.6 nM [1].

Febuxostat dicarboxylic acid impurity is a byproduct of Febuxostat, a selective xanthine oxidase inhibitor with a K_i of 0.6 nM [1].

Febuxostat amide impurity, an impurity of Febuxostat, is associated with the selective xanthine oxidase inhibitor Febuxostat, which has a K_i of 0.6 nM [1].

Febuxostatimpurity 50 is a contaminant associated with Febuxostat.

Febuxostat-D9 is deuterium labeled Febuxostat (TMSM-3473), which is a selective xanthine oxidase inhibitor with Ki of 0.6 nM.

Febuxostat Acyl Glucuronide is the primary metabolite of the potent xanthine oxidase (XO) inhibitor Febuxostat. It is formed through the glucuronidation of the carboxylic acid group of Febuxostat, a process mediated by UDP-glucuronosyltransferase (UGT) enzymes. The production of this acyl glucuronide is a major elimination pathway for the parent drug. Researching this metabolite is essential for characterizing metabolic clearance, understanding drug-drug interactions, and evaluating the pharmacokinetic variability of Febuxostat across different patient populations, including those with UGT enzymatic polymorphisms.

Febuxostat 67M-2 is a derivative of Febuxostat 67M-1, which is a xanthine oxidase inhibitor. Febuxostat 67M-2 reduces the production of uric acid in the body and is used to lower the risk of gout or kidney stones.

Febuxostat-D7 is a deuterated compound of Febuxostat. Febuxostat (T0773) has a CAS number of 144060-53-7. Febuxostat (T0773) is a xanthine oxidase Inhibitor.

Febuxostat (Standard) is a reference standard for research and analysis in studies involving Febuxostat. Febuxostat (TEI 6720) is a xanthine oxidase Inhibitor.

Febuxostat D9 (Standard) is a reference standard of Febuxostat D9 intended for quantitative analysis, quality control, and related biochemical research applications. Febuxostat D9 is deuterium labeled Febuxostat, which is a selective xanthine oxidase inhibitor with Ki of 0.6 nM.